Company Overview

Codexis, Inc. is a U.S.-based biotechnology company focused on developing and engineering enzymes for applications across the pharmaceutical manufacturing, life sciences, and industrial biotechnology sectors. The company operates primarily within the enzyme engineering and synthetic biology industries, using its proprietary protein engineering platform to optimize enzymes for improved performance, efficiency, and scalability. Codexis generates revenue through product sales, research and development collaborations, licensing agreements, and milestone payments associated with partnered programs.

The company’s core business historically centered on supplying engineered enzymes used in the manufacture of active pharmaceutical ingredients for major biopharmaceutical companies. In recent years, Codexis expanded into nucleic acid synthesis and genomic medicine tools, particularly through engineered enzymes used in RNA and DNA applications. A distinguishing strategic advantage is its proprietary CodeEvolver® technology platform, which enables rapid enzyme optimization through directed evolution techniques. Codexis was founded in 2002 and evolved from an industrial biocatalysis company into a broader biotechnology platform company serving pharmaceutical manufacturing and emerging genomic medicine markets.

Business Operations

Codexis operates through a single reportable segment focused on enzyme engineering and related biotechnology solutions. Its business activities include the commercialization of engineered enzymes, licensing of its protein engineering technology, and collaborative research programs with pharmaceutical and biotechnology companies. Revenue is derived from enzyme product sales, licensing fees, development services, milestone payments, and royalties tied to customer commercialization activities. The company has maintained long-term relationships with major pharmaceutical manufacturers for use of biocatalysts in drug production processes.

The company’s operational capabilities are centered around its proprietary CodeEvolver® protein engineering platform and related intellectual property portfolio. Codexis has engaged in partnerships and strategic collaborations with companies involved in RNA therapeutics, molecular biology tools, and pharmaceutical manufacturing. Historically, collaborations have included relationships with large pharmaceutical firms and life sciences companies focused on nucleic acid synthesis technologies. Operations are primarily based in the United States, though the company supports customers and commercial activities internationally through direct relationships and distribution arrangements.

Strategic Position & Investments

Codexis has increasingly positioned itself toward higher-growth areas within synthetic biology and genomic medicine, particularly enzyme solutions for RNA synthesis, oligonucleotide manufacturing, and molecular biology workflows. The company has invested in expanding applications of its enzyme engineering technology beyond traditional pharmaceutical manufacturing into life sciences tools and next-generation therapeutic development. Management has identified nucleic acid synthesis and RNA-enabled therapeutics as strategic growth areas alongside its established pharmaceutical biocatalysis business.

The company has also pursued strategic partnerships and internal development initiatives aimed at expanding its technology platform and commercial reach. Codexis has invested in enhancing enzyme performance for large-scale manufacturing processes and genomic medicine applications, including enzymes used in RNA synthesis workflows. Public filings and investor disclosures indicate that management has prioritized partnerships, intellectual property development, and platform commercialization as central components of long-term strategy. Data regarding certain prospective commercial applications remains dependent on future customer adoption and regulatory developments.

Geographic Footprint

Codexis is headquartered in Redwood City, California, and primarily conducts research, development, and corporate operations in the United States. The company serves customers across multiple regions, including North America, Europe, and Asia-Pacific, particularly within pharmaceutical and biotechnology manufacturing markets. Its customer base includes multinational pharmaceutical companies and life sciences organizations operating globally.

Although Codexis does not maintain the same international manufacturing footprint as larger industrial biotechnology firms, its technologies and enzyme products are integrated into global pharmaceutical production and research workflows. The company’s commercial influence extends internationally through licensing agreements, customer collaborations, and distribution relationships supporting enzyme applications in regulated pharmaceutical and biotechnology markets.

Leadership & Governance

Codexis is led by an executive management team with experience in biotechnology, pharmaceuticals, life sciences commercialization, and enzyme engineering. The company’s governance structure includes a board of directors overseeing corporate strategy, operational performance, and long-term technology development initiatives. Leadership has consistently emphasized platform-driven growth, strategic partnerships, and expansion into higher-value life sciences applications.

Key executives include:

• Stephen Dilly – Chief Executive Officer and Director
• Ross Taylor – Senior Vice President and Chief Financial Officer
• Alison Moore – President
• Dennis P. Wolf – Senior Vice President, Legal Affairs, General Counsel and Corporate Secretary
• Kashif Azim – Senior Vice President, Operations

Management’s strategic vision has focused on leveraging the company’s proprietary enzyme engineering capabilities to expand beyond traditional industrial biocatalysis into genomic medicine, RNA synthesis, and advanced therapeutic manufacturing technologies.